Wedbush Maintains Neutral on Abivax, Raises Price Target to $110
Wedbush analyst David Nierengarten maintains Abivax (NASDAQ: ABVX ) with a Neutral and raises the price target from $90 to $110.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.